Department of Radiotherapy, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Thorac Cancer. 2022 Mar;13(5):659-663. doi: 10.1111/1759-7714.14335. Epub 2022 Feb 2.
The role of adjuvant radiotherapy in completely resected pIIIA-N2 non-small cell lung cancer (NSCLC) has long been debated. Evidence from previous retrospective and prospective studies showed that postoperative radiotherapy could reduce the incidence of local recurrence and prolong disease-free survival, while two recently reported randomized controlled trials (lung ART and PORT-C) both demonstrated no survival benefit of postoperative radiotherapy. The great gap between our knowledge and reality has made us rethink the value of postoperative radiotherapy. In this mini review, we elaborate on the role of postoperative radiotherapy in completely resected pIIIA-N2 NSCLC.
完全切除的 IIIA-N2 期非小细胞肺癌(NSCLC)辅助放疗的作用一直存在争议。来自先前回顾性和前瞻性研究的证据表明,术后放疗可降低局部复发率并延长无病生存期,而最近两项随机对照试验(lung ART 和 PORT-C)均未显示术后放疗有生存获益。我们的知识和现实之间的巨大差距使我们重新思考术后放疗的价值。在这篇迷你综述中,我们详细阐述了完全切除的 IIIA-N2 期 NSCLC 术后放疗的作用。